1. Home
  2. RENX vs XRTX Comparison

RENX vs XRTX Comparison

Compare RENX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

HOLD

Current Price

$1.06

Market Cap

4.2M

Sector

N/A

ML Signal

HOLD

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RENX
XRTX
Founded
2021
2011
Country
United States
Canada
Employees
38
N/A
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
3.9M
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
RENX
XRTX
Price
$1.06
$1.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
122.6K
★ 358.6K
Earning Date
11-13-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $8,220,449.00
N/A
Revenue This Year
$109.28
N/A
Revenue Next Year
$53.56
$392.31
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3860.67
N/A
52 Week Low
$1.15
$0.35
52 Week High
$203.14
$3.60

Technical Indicators

Market Signals
Indicator
RENX
XRTX
Relative Strength Index (RSI) 25.38 37.23
Support Level N/A $0.37
Resistance Level $2.12 $2.26
Average True Range (ATR) 0.19 0.23
MACD -0.07 -0.04
Stochastic Oscillator 8.22 21.03

Price Performance

Historical Comparison
RENX
XRTX

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Share on Social Networks: